Jefferies Reiterates Buy on Aratana Therapeutics (PETX) Following US Galliprant Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Aratana Therapeutics to Present GALLIPRANT® (grapiprant tablets) Pivotal Data
March 31, 2016 9:00 AM EDTLEAWOOD, Kan., March 31, 2016 /PRNewswire/ --Â Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the Company plans to showcase Galliprant pivotal efficacy and safety data at the American Animal Hospital Association (AAHA) annual conference in Austin, Texas on Saturday, April 2, 2016 from 7:00 7:50 a.m. Lesley Rausch-Derra, DVM, MS, Vice President of Regulatory Affairs and Drug Development at Aratana Therapeutics, will present the pivotal data during the Sunrise Session for registered conference attendees. Presentation slides are also... More
